<DOC>
	<DOCNO>NCT00214825</DOCNO>
	<brief_summary>Specific aim proposal determine patient diabetes mellitus effect aldosterone receptor antagonist : 1 . Coronary microvascular function assess MRI perfusion reserve , 2 . Endothelial dysfunction assess brachial artery reactivity study , 3 . Inflammation assess blood measurement c-reactive protein ( CRP ) , monocyte chemoattractant protein-1 ( MCP-1 ) , plasminogen activator inhibitor-1 ( PAI-1 ) .</brief_summary>
	<brief_title>Aldosterone Vascular Disease Diabetes Mellitus</brief_title>
	<detailed_description>Recent human animal study suggest activation mineralocorticoid receptor ( MR ) aldosterone , final product renin-angiotensin-aldosterone system , cause microvascular damage , vascular inflammation , endothelial dysfunction . Angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARBs ) unable provide long-term aldosterone suppression . Therefore , hypothesize activation MR contribute progression vascular disease patient diabetes already use ACE inhibitor therapy . Specific aim proposal determine patient type 1 type 2 diabetes mellitus proteinuria , already receive ACE inhibitor ARB therapy , effect aldosterone receptor antagonist vs. hydrochlorothiazide : 1 . Coronary microvascular function assess MRI perfusion reserve , 2 . Endothelial dysfunction assess brachial artery reactivity study , 3 . Inflammation cellular oxidative stress injury , assess c-reactive protein ( CRP ) , MCP-1 , plasminogen activator inhibitor-1 ( PAI-1 ) . 4 . Proteinuria whether differential effect MR antagonist HCTZ add ACE inhibitor therapy . This double-blind , randomize , cross-over study men woman ( 21-64 year old ) type 1 type 2 diabetes mellitus albuminuria ( ³30 mg/g creatinine ) . Participants randomize MR antagonist + placebo HCTZ + potassium supplementation 6 week . The MR antagonist arm receive eplerenone 50 mg daily . The HCTZ arm receive HCTZ 12.5 mg potassium 10 Meq daily . Amlodipine 5 10 mg daily add run phase control blood pressure . Blood pressure goal le 130/80 mm Hg . There 4-week washout period patient crossed-over study arm . MRI perfusion reserve , brachial artery reactivity , blood sample obtain begin end treatment arm .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Men woman ( 2164 year old ) type 1 type 2 diabetes mellitus albuminuria ( 30 mg/g creatinine ) . Exclusion criterion include : ( 1 ) subject without hypertension baseline systolic blood pressure &lt; 100 mmHg , ( 2 ) severe hypertension ( blood pressure must wellcontrolled 3 antihypertensive agent &lt; 150/100 mmHg £2 antihypertensive agent ) , ( 3 ) ischemic change rest electrocardiogram , ( 4 ) clinical evidence heart disease , cerebrovascular peripheral vascular disease , ( 5 ) significant cardiac arrhythmia , ( 6 ) aortic stenosis , ( 7 ) 2nd 3rd degree atrioventricular block , sinus node disease , symptomatic bradycardia , ( 8 ) bronchospastic lung disease active wheezing , ( 9 ) know hypersensitivity study drug , ( 10 ) contraindication MRI , ( 11 ) serum creatinine ³ 1.5 mg/dL , ( 12 ) serum potassium ³ 5.0 mmol/L , ( 13 ) current smoker , ( 14 ) Serum transaminase great twice upper limit normal , ( 15 ) history gout , ( 16 ) pregnancy , ( 17 ) active medical problem detect examination laboratory testing .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>